Preparation of 177Lu-PSMA-617 in Hospital Radiopharmacy: Convenient Formulation of a Clinical Dose Using a Single-Vial Freeze-Dried PSMA-617 Kit Developed In-House
Objective. In the recent time, endoradionuclide therapy for metastatic castration-resistant prostate carcinoma employing 177Lu-PSMA-617 has yielded encouraging results and several clinical trials with the agent are currently ongoing. Routine preparation of 177Lu-PSMA-617 patient doses can be made si...
Guardado en:
Autores principales: | Mohini Guleria, Jeyachitra Amirdhanayagam, Haladhar D. Sarma, Ramya Priya Rallapeta, V. S. Krishnamohan, Ajit Nimmagadda, Parthasarathy Ravi, Sailaja Patri, Tekchand Kalawat, Tapas Das |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Hindawi Limited
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/51bd0afc08974ec99e5dcbba92b83e22 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
por: Madhav Prasad Yadav, et al.
Publicado: (2021) -
Separation of <sup>44</sup>Sc from <sup>44</sup>Ti in the Context of A Generator System for Radiopharmaceutical Purposes with the Example of [<sup>44</sup>Sc]Sc-PSMA-617 and [<sup>44</sup>Sc]Sc-PSMA-I&T Synthesis
por: Anton A. Larenkov, et al.
Publicado: (2021) -
PSMA expression by microvasculature of thyroid tumors – Potential implications for PSMA theranostics
por: Andrey Bychkov, et al.
Publicado: (2017) -
Acta Nº617
por: Banco Central de Chile
Publicado: (2019) -
Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
por: Bastiaan M. Privé, et al.
Publicado: (2021)